ondansetron has been researched along with Anorexia in 7 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Anorexia: The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Effects of some selective serotonergic (5-HT) antagonists on methamphetamine-induced anorexia were investigated in male mice." | 7.73 | Ondansetron, a selective 5-HT3 antagonist, antagonizes methamphetamine-induced anorexia in mice. ( Al-Majed, AA; Al-Suwailem, AK; Ginawi, OT, 2005) |
| " Both drugs showed similar results in regard to chemotherapy-induced gastrointestinal side effects, emesis and appetite loss on day 1, but by day 5, ramosetron was significantly better than ondansetron in terms of controlling appetite loss." | 5.12 | Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study. ( Ai, B; Dong, M; Han, X; He, X; Huang, D; Liu, P; Shi, Y; Yang, S; Zhang, C; Zhou, S, 2007) |
| "Eighty-five in-patients with cancer undergoing chemotherapy were randomly divided into 2 groups: Nasea group (group A, n = 43, Nasea, ramosetron hydrochloride was injected intravenously 30 minutes before chemotherapy) and ondansetron group (group B, n = 42, ondamsetron was injected intravenously 30 minutes before chemotherapy)." | 2.71 | [Effects of Nasea on prevention of gastrointestinal side effects caused by chemotherapeutic drugs]. ( Liu, DW; Liu, YY; Shan, XJ; Xie, XD; Zheng, ZD, 2003) |
| "Patients with metastatic cancer who were not undergoing chemotherapy or radiotherapy and who had lost >5% of their body weight were eligible." | 2.69 | Serotonergic blockade in the treatment of the cancer anorexia-cachexia syndrome. ( Edelman, MJ; Gandara, DR; Gietzen, DW; Houston, J; Ishii, R; Lauder, I; Meyers, FJ; O'Mahony, M; Uhrich, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Leon, RM | 1 |
| Borner, T | 1 |
| Reiner, DJ | 1 |
| Stein, LM | 1 |
| Lhamo, R | 1 |
| De Jonghe, BC | 1 |
| Hayes, MR | 1 |
| Yakabi, K | 1 |
| Kurosawa, S | 1 |
| Tamai, M | 1 |
| Yuzurihara, M | 1 |
| Nahata, M | 1 |
| Ohno, S | 1 |
| Ro, S | 1 |
| Kato, S | 1 |
| Aoyama, T | 1 |
| Sakurada, T | 1 |
| Takabayashi, H | 1 |
| Hattori, T | 1 |
| Xie, XD | 1 |
| Zheng, ZD | 1 |
| Liu, DW | 1 |
| Liu, YY | 1 |
| Shan, XJ | 1 |
| Ginawi, OT | 1 |
| Al-Majed, AA | 1 |
| Al-Suwailem, AK | 1 |
| Shi, Y | 1 |
| He, X | 1 |
| Yang, S | 1 |
| Ai, B | 1 |
| Zhang, C | 1 |
| Huang, D | 1 |
| Dong, M | 1 |
| Liu, P | 1 |
| Zhou, S | 1 |
| Han, X | 1 |
| Wilkes, G | 1 |
| Edelman, MJ | 1 |
| Gandara, DR | 1 |
| Meyers, FJ | 1 |
| Ishii, R | 1 |
| O'Mahony, M | 1 |
| Uhrich, M | 1 |
| Lauder, I | 1 |
| Houston, J | 1 |
| Gietzen, DW | 1 |
3 trials available for ondansetron and Anorexia
| Article | Year |
|---|---|
[Effects of Nasea on prevention of gastrointestinal side effects caused by chemotherapeutic drugs].
Topics: Adult; Aged; Anorexia; Antiemetics; Antineoplastic Agents; Benzimidazoles; Female; Gastrointestinal | 2003 |
Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study.
Topics: Adolescent; Adult; Aged; Anorexia; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benz | 2007 |
Serotonergic blockade in the treatment of the cancer anorexia-cachexia syndrome.
Topics: Adult; Aged; Anorexia; Cachexia; Dietary Proteins; Female; Humans; Male; Middle Aged; Neoplasms; Nut | 1999 |
4 other studies available for ondansetron and Anorexia
| Article | Year |
|---|---|
Hypophagia induced by hindbrain serotonin is mediated through central GLP-1 signaling and involves 5-HT2C and 5-HT3 receptor activation.
Topics: Animals; Anorexia; Feeding Behavior; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Lith | 2019 |
Rikkunshito and 5-HT2C receptor antagonist improve cisplatin-induced anorexia via hypothalamic ghrelin interaction.
Topics: Animals; Anorexia; Cisplatin; Drugs, Chinese Herbal; Eating; Gastric Mucosa; Ghrelin; Granisetron; H | 2010 |
Ondansetron, a selective 5-HT3 antagonist, antagonizes methamphetamine-induced anorexia in mice.
Topics: Animals; Anorexia; Eating; Male; Methamphetamine; Mice; Ondansetron; Receptors, Serotonin, 5-HT3; Se | 2005 |
Antiemetic agents.
Topics: Administration, Oral; Anorexia; Antiemetics; Antineoplastic Agents; Aprepitant; Asthenia; Constipati | 2007 |